Zhejiang Changhai Pharmaceutical Co., Ltd. ("Changhai Pharmaceutical"), a holding subsidiary of Zhejiang Medicine Co., Ltd. ("the Company"), received the Approval Notice for the Marketing Application of Empagliflozin Active Pharmaceutical Ingredient (Notice No.: 2024YS00344) issued and verified by the National Medical Products Administration ("NMPA") on April 25, 2024. The relevant details are hereby announced as follows:
I. Basic Information of the Drug
Name of Active Pharmaceutical Ingredient (API): Empagliflozin
Registration Standard No.: YBY62862024
Packaging Specifications: 5kg/drum, 10kg/drum, 15kg/drum, 20kg/drum
Manufacturer: Zhejiang Changhai Pharmaceutical Co., Ltd.
Manufacturer Address: No. 188 Zhiyuan Middle Avenue, Shaoxing Binhai New City
Application Item: Marketing application for domestically manufactured chemical API
Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China, upon review, this product complies with the relevant provisions on API approval, and the production of this product is approved. The quality standard, packaging labels and production process shall be implemented in accordance with the attached documents.
II. Other Relevant Information of the Drug
Empagliflozin is indicated for the treatment of type 2 diabetes mellitus. In combination with diet control and exercise, this product is used to improve glycemic control in adult patients with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Empagliflozin is the third sodium-glucose cotransporter 2 (SGLT-2) inhibitor approved by the U.S. Food and Drug Administration (FDA). It works by reducing renal glucose reabsorption, lowering the renal glucose threshold and promoting urinary glucose excretion. Empagliflozin is the first anti-diabetic drug approved by the United States and the European Union to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus. It has also been approved as a therapy for all adult patients with symptomatic chronic heart failure, including patients with all types of left ventricular ejection fraction (LVEF), namely heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
The original research and development company of Empagliflozin is Boehringer Ingelheim. Empagliflozin tablets were approved for marketing in the United States in 2014 and in China in 2017. According to the Minenet database, the domestic sales volume of empagliflozin tablets reached approximately RMB 571 million in 2022. At present, APIs of empagliflozin produced by 17 domestic pharmaceutical enterprises have been approved for use in preparations, including Zhejiang Huahai Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Yangzijiang Pharmaceutical Group Co., Ltd. and Lianyungang Recbio Pharmaceutical Co., Ltd.
In September 2022, Changhai Pharmaceutical submitted the registration and marketing application for the API to NMPA, which was accepted. Up to now, the Company has invested a total of approximately RMB 26.1752 million in research and development expenses for the empagliflozin API project.












